Lunai Bioworks Inc.
LNAI
Get informed when a big investor buys or sells
+ FollowMarket Cap$2.58M
Close$
$-0.61
174% downside
Current Fair Value
174% downsideOvervalued by 174% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $2.58 Million |
|---|---|
| Enterprise Value | $835,184.00 |
| Dividend Yield | $- (-) |
| Earnings per Share | $-86.24 |
| Beta | 0.35 |
| Outstanding Shares | 3,124,275 |
Return
| Return on Equity | 1342.81% |
|---|---|
| Return on Assets | -1300.98% |
| Return on Invested Capital | 1346.34% |
Valuation & Multiples
| P/E Ratio | -0.02 |
|---|---|
| PEG | 0 |
| Price to Sales | - |
| Price to Book Ratio | -0.21 |
| Enterprise Value to Revenue | 39.88 |
| Enterprise Value to EBIT | -0.01 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 1.69 |
| Debt to Equity | -0.15 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
October 13, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
November 12, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Lunai Bioworks Inc.
29 employees
CEO: David Weinstein A company rebranding from Renovaro, focusing on AI-powered therapeutics and biodefense, with “Neurotoxicity Intelligence Technology” in development.